The regulatory acceptance of application for marketing authorisation of tislelizumab is to treat first-line unresectable or metastatic HCC patients. The humanised IgG4 anti-PD-1 monoclonal antibody tislelizumab has been
The company submitted the vaccine candidate to prevent meningococcal disease, which is caused by the most common serogroups, in individuals aged 10 to 25 years. MenABCWY combines the
Olpruva is a prescription medicine which has been approved as an oral suspension to treat UCD patients with deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic
Under the deal terms, Hikma will have an exclusive right to develop and market toripalimab injection in all its Middle East and North Africa (MENA) markets. Additionally, the
NexoBrid is indicated to remove eschar in paediatric and adult patients with deep-partial and full-thickness thermal burns without surgery. Japan is claimed to be the world’s first country
The treatment is intended for such patients who have previously received two or more lines of systemic therapy. The JNDA filing is backed by the multicentre, open-label Phase
Under the deal, Vistagen will offer nearly 12.4 million shares of the company’s common stock as well as a nominal cash payment. Pherin works on discovering and developing
Kite will purchase all outstanding shares of Tmunity other than those the company already owns. The acquisition complements the existing in-house cell therapy research capabilities of Kite with
ENHERTU is a particularly engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialised by the two firms. Around 136,000 cases of gastric cancer are diagnosed
Innovate UK awarded the grant as part of its Biomedical Catalyst 2022 research and development (R&D) competition. Alchemab is currently undertaking the preclinical studies to progress its antibodies
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.